FMC Corporation (FMC)
NYSEMaterialsAgricultural InputsSnapshot 2026-09-14
$10.98-3.68%
Close 2026-09-14 · 1-day change
NYSEMaterialsAgricultural InputsSnapshot 2026-09-14
Research Workspace
Put FMC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — EPS near $1.76 per share: FY26 EPS guidance $1.19-$1.49 vs target $1.63.
View ThesisRevenue is contracting — down about 21% over the past year.
View GrowthManagement screens weak on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 73% in its worst 12-month stretch.
View RiskFMC's growth depends on its ability to improve earnings quality and execute its buyback program. Revenue has been weak, with a recent earnings beat of 24% but a year-over-year revenue decline of 17%. It trades at 5.4× P/E, below the 17.6× peer median, indicating that the price reflects less growth than expected. The primary risk is the company's fragile earnings quality, as reported profits are not well backed by cash. Peer multiples imply a price about 34% above where it trades. This read is provisional.
Trailing returns as of 2026-09-14. FMC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering FMC (as of Sep 2026).
Based on 8 Wall Street analysts offering 12-month price targets for FMC in the last 4 months.
Continue this research
Compare FMC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| FMC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Fertilizers & Agricultural Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put FMC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Announce and execute share buyback program
Cuts outlook indicates potential difficulties in executing share buyback.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $10.98
The last 12 months of price, then the range of analyst 12-month targets from today’s $10.98.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Drive growth of new active ingredients
New active ingredient approval supports growth strategy.
Threatens: Strengthen balance sheet by reducing debt by $1 billion
Debt solution raises concerns about balance sheet strength.
Strategic investment may enhance growth and validate market position.
Advances: Explore strategic options including potential sale
Strategic partnership enhances growth potential through new product offerings.
Advances: Explore strategic options including potential sale
Sale of India business aligns with strategic options exploration.
Advances: Strengthen balance sheet by reducing debt by $1B
Debt paydown target supports balance sheet strengthening objective.
Advances: Drive growth of new active ingredients
Approval for Isoflex supports growth of new active ingredients.